Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Titel:
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Auteur:
Sheppard, Michael Bronstein, Marcello D. Freda, Pamela Serri, Omar Marinis, Laura De Naves, Luciana Rozhinskaya, Liudmila Hermosillo Reséndiz, Karina Ruffin, Matthieu Chen, YinMiao Colao, Annamaria